Trusted therapy
supported by Indian
and International Studies
US FDA approved for the
prevention of recurrent
spontaneous preterm birth
ACOG’s clinical guidance
recognizes as ‘Prediction and
Prevention’ of preterm birth
|
Dosage form: |
Depot Release Injection |
Therapeutic Class: |
Progestogen for progesterone deficiency during pregnancy |
|
Composition: |
17α-Hydroxyprogesterone Caproate – 250mg/ml |
Packing Monocarton: |
17α-Progestogen for progesterone deficiency during pregnancy |
|
Strengths available: |
500mg and 250mg |
|
Dosage form: |
Depot Release Injection |
|
Therapeutic Class: |
Progestogen for progesterone deficiency during pregnancy |
|
Composition: |
17α-Hydroxyprogesterone Caproate – 250mg/ml |
|
Packing Monocarton: |
17α-Progestogen for progesterone deficiency during pregnancy |
|
Strengths available: |
500mg and 250mg |
